Trials / Completed
CompletedNCT00628212
Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes
A Phase II, Double-Blind, Placebo-Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus -Confirmative Study-
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 324 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety and to determine the appropriate dose for phase 3 confirmatory trial, of MP-513 (Teneligliptin) in patients with type 2 Diabetes based on the change of HbA1c and adverse events after 12 weeks administration once daily in multi-center, randomized, double-blind, placebo-controlled, parallel assignment manner.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teneligliptin 10mg | |
| DRUG | Teneligliptin 20 mg | |
| DRUG | Teneligliptin 40 mg | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-12-01
- Completion
- 2009-01-01
- First posted
- 2008-03-04
- Last updated
- 2026-01-02
- Results posted
- 2013-05-31
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00628212. Inclusion in this directory is not an endorsement.